Gosebruch Henry O
Gosebruch Henry O's purchase track record
Gosebruch Henry O has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/19/2023 | NMRA | $189K | +21.4% | +17.1% | +16.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.
Transaction History
| ANIP | ▲ Buy | Grant | 6,662 | $0 | 8/19/2026 | View on chart |
| NMRA | ▲ Buy | Grant | 80,000 | $0 | 2/14/2024 | View on chart |
| NMRA | ▲ Buy | Open Market | 15,000 | $189K | 9/19/2023 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 83,960 | $4.6M | 5/16/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 83,960 | $13.0M | 5/16/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 15,733 | $2.3M | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 5,167 | $763K | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 4,000 | $595K | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 100 | $15K | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 5,596 | $826K | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 8,303 | $1.2M | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Open Market | 1,101 | $164K | 3/1/2022 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 30,156 | $4.5M | 2/25/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 36,673 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 7,972 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 14,722 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 8,701 | $0 | 2/17/2022 | View on chart |
| ABBV | ▼ Sell | Gift | 30,000 | $0 | 9/7/2021 | View on chart |
| ABBV | ▼ Sell | Gift | 30,000 | $0 | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results
ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results. ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.